全髋或全膝关节置换术后静脉血栓栓塞的预防。
完整摘要 · 中文译文
背景:比较阿司匹林与抗凝药用于全髋或全膝关节置换术后静脉血栓栓塞症(VTE)预防的研究结果存在矛盾。 方法:在一项比较有效性非劣效性试验中,我们将接受择期髋或膝关节置换术的患者随机分配接受阿司匹林(81 mg,每日两次)、华法林(目标国际标准化比值为2.0)或利伐沙班(10 mg,每日一次)治疗30天。复合主要有效性结局(任何原因死亡或有症状VTE)和主要安全性结局(出血、因伤口问题再次手术或心肌梗死)以盲法评估至6个月。风险差的非劣效性界值为0.69个百分点。 结果:在18,883例接受随机分组的参与者中,15,317例(7214例髋关节置换术和8103例膝关节置换术)被纳入主要符合方案分析。阿司匹林组6090例参与者中有77例(1.26%)发生主要有效性结局事件,华法林组4231例中有52例(1.23%),利伐沙班组4996例中有47例(0.94%);主要安全性结局事件分别发生于177例(2.91%)、142例(3.36%)和174例(3.48%)。在成对比较中,阿司匹林与利伐沙班的6个月主要有效性结局事件风险分别为1.24%和0.94%(差异,0.30个百分点;95%置信区间[CI],-0.20至0.81);阿司匹林与华法林分别为1.24%和1.01%(差异,0.23个百分点;95% CI,-0.34至0.81);以及华 利伐沙班与华法林相比(差异,0.03个百分点;95% CI,-0.57至0.63)。利伐沙班与阿司匹林相比,主要安全性结局事件风险分别为3.70%和3.02%(差异,0.68个百分点;95% CI,-0.04至1.41);华法林与阿司匹林相比分别为3.65%和2.88%(差异,0.77个百分点;95% CI,-0.04至1.58);利伐沙班与华法林相比分别为3.59%和3.61%(差异,-0.02个百分点;95% CI,-0.89至0.85)。意向性治疗分析得到了相似的结果。 结论:在全髋或全膝关节置换术后,就死亡或有症状静脉血栓栓塞症(VTE)而言,阿司匹林预防并不非劣于利伐沙班或华法林。就安全性而言,华法林和利伐沙班并不非劣于阿司匹林。(由患者中心结局研究所资助;PEPPER ClinicalTrials.gov注册号,NCT02810704。)
完整摘要 · 英文原文
BACKGROUND: Studies comparing aspirin with anticoagulants for venous thromboembolism (VTE) prophylaxis after total hip or knee arthroplasty have had conflicting results. METHODS: In a comparative-effectiveness noninferiority trial, we randomly assigned patients undergoing elective hip or knee arthroplasty to receive aspirin (81 mg twice daily), warfarin (to a target international normalized ratio of 2.0), or rivaroxaban (10 mg daily) for 30 days. The composite primary effectiveness outcome (death from any cause or symptomatic VTE) and primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) were evaluated through 6 months in a blinded fashion. The noninferiority margin for the risk difference was 0.69 percentage points. RESULTS: Among 18,883 participants who had undergone randomization, 15,317 (7214 with hip arthroplasty and 8103 with knee arthroplasty) were included in the primary per-protocol analysis. A primary effectiveness outcome event occurred in 77 of 6090 participants (1.26%) in the aspirin group, in 52 of 4231 (1.23%) in the warfarin group, and in 47 of 4996 (0.94%) in the rivaroxaban group; a primary safety outcome event occurred in 177 (2.91%), 142 (3.36%), and 174 (3.48%), respectively. In pairwise comparisons, 6-month risks of a primary effectiveness outcome event were 1.24% and 0.94% for aspirin versus rivaroxaban (difference, 0.30 percentage points; 95% confidence interval [CI], -0.20 to 0.81); 1.24% and 1.01% for aspirin versus warfarin (difference, 0.23 percentage points; 95% CI, -0.34 to 0.81); and 1.13% and 1.10% for warfarin versus rivaroxaban (difference, 0.03 percentage points; 95% CI, -0.57 to 0.63). Risks of a primary safety outcome event were 3.70% and 3.02% for rivaroxaban versus aspirin (difference, 0.68 percentage points; 95% CI, -0.04 to 1.41); 3.65% and 2.88% for warfarin versus aspirin (difference, 0.77 percentage points; 95% CI, -0.04 to 1.58); and 3.59% and 3.61% for rivaroxaban versus warfarin (difference, -0.02 percentage points; 95% CI, -0.89 to 0.85). Intention-to-treat analyses yielded similar results. CONCLUSIONS: Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).